Selank 5mg

Selank is a synthetic peptide derived from tuftsin, a natural peptide involved in immune system regulation. While initially studied for its immune-modulating properties, Selank has gained significant attention for its potential neuroprotective and anxiolytic effects.

How Does Selank Work?

Selank exerts its effects through various mechanisms, including:

• GABAergic Modulation: Selank enhances the activity of GABA, a neurotransmitter known for its calming and inhibitory effects. By increasing GABAergic activity, Selank can reduce anxiety and promote relaxation.
• Enkephalin Protection: Selank inhibits the degradation of enkephalins, natural pain-relieving peptides. This can contribute to its anxiolytic and pain-reducing effects.
• Neuroprotective Effects: Selank may protect neurons from damage by reducing oxidative stress and inflammation.

Potential Benefits of Selank

• Anxiolytic Effects: Selank has been shown to reduce anxiety and promote calmness.
• Neuroprotection: It may protect neurons from damage, potentially slowing cognitive decline.
• Immune Modulation: Selank can modulate the immune system, enhancing its function.
• Pain Reduction: By increasing enkephalin levels, Selank may help alleviate pain.

Important Considerations

• Regulatory Status: While Selank is approved for medical use in some countries, it is not FDA-approved in the United States.
• Limited Research: While promising, research on Selank is still relatively limited.
• Potential Side Effects: Selank is generally well-tolerated, but it may cause mild side effects like drowsiness or headache in some individuals.

References

1. National Center for Biotechnology Information (2021). PubChem Substance Record for SID 319341034, 189691-06-3, Source: ToxPlanet. Retrieved October 21, 2021 from https://pubchem.ncbi.nlm.nih.gov/substance/319341034.
2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Bremelanotide. 2021 Aug 20. PMID: 34436837.
3. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019 Sep;79(14):1599-1606. doi: 10.1007/s40265-019-01187-w. PMID: 31429064.
4. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. PMID: 31893927.
5. Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2019 Jul 29;61(1577):114-116. PMID: 31381550.
6. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003 Jun;994:96-102. doi: 10.1111/j.1749-6632.2003.tb03167.x. PMID: 12851303.
7. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004 Apr;16(2):135-42. doi: 10.1038/sj.ijir.3901200. PMID: 14999221.
8. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):51-9. doi: 10.1038/sj.ijir.3901139. PMID: 14963471.
9. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008 Mar;179(3):1066-71. doi: 10.1016/j.juro.2007.10.063. Epub 2008 Jan 18. PMID: 18206919.
10. Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2021 Jan 18:1-9. doi: 10.1017/S109285292100002X. Epub ahead of print. PMID: 33455598.
11. Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., Kaminetsky, J., Spana, C., Lucas, J., Jordan, R., & Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s health (London, England), 12(3), 325–337. https://doi.org/10.2217/whe-2016-0018
12. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
13. (2021). Retrieved 10 October 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
14. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106. PMID: 17584130; PMCID: PMC2694735.
15. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019 Nov;134(5):909-917. doi: 10.1097/AOG.0000000000003514. PMID: 31599847; PMCID: PMC6819023.
16. Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019 Aug;16(8):1226-1235. doi: 10.1016/j.jsxm.2019.05.012. Epub 2019 Jul 2. PMID: 31277966.